Cellectis pivots to in vivo gene editing, restructures operations to extend cash runway into H2 2028
CLLS•Cash runway extended
Cost actions aim to extend cash runway into H2 2028.
Pipeline changes and partnerships
Development of lasme-cel and eti-cel will end, with partnering pursued, reflecting a weaker outlook for B-ALL and NHL opportunities.
Operations will be resized to support the new pipeline while maintaining existing cell therapy partnerships with AstraZeneca, Allogene, Servier, and Iovance.
Strategic pivot to in vivo gene editing
Cellectis will reorganize to pivot from cell therapy development to an in vivo gene-editing strategy focused on chronic diseases.
Two lead programs, HEAL-101 and HEAL-201, will advance toward Phase 1 investigator-initiated trials in China.
